参考文献/References:
[1] Parsons DW, Jones S, Zhang X, et al. An integrated genomic
analysis of human glioblastoma multiforme [J]. Science,
2008, 321(5897): 1807-1812.
[2] álvarez de Eulate-Beramendi S, álvarez-Vega MA, Balbin
M, et al. Prognostic factors and survival study in high-grade
glioma in the elderly [J]. Br J Neurosurg, 2016, 30(3): 330-
336.
[3] Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an
early and consistent marker in low-grade astrocytomas
WHO grade II and their consecutive secondary high-grade
gliomas [J]. J Neuro-oncol, 2012, 108(3): 403-410.
[4] Louis DN, Perry A, Reifenberger G, et al. The 2016 World
Health Organization Classification of Tumors of the Central
Nervous System: a summary [J]. Acta Neuropathol, 2016,
131(6): 803-820.
[5] 王修成，王新军，曾凡涛. IDH-1在胶质瘤中的表达及相
关因素分析[J]. 中国实用神经疾病杂志，2018，21（22）：
2450-2455.
[6] 茆晨雪，周宏灏，刘昭前. 弥漫性胶质瘤生物标志物的发
现及研究进展[J]. 中国临床药理学与治疗学，2016，21
（1）：93-98.
[7] Reiter-Brennan C, Semmler L, Klein A. The effects of 2-
hydroxyglutarate on the tumorigenesis of gliomas [J]. Con-
temp Oncol (Pozn), 2018, 22(4): 215-222.
[8] Sun C, Zhao Y, Shi J, et al. Isocitrate dehydrogenase1 muta-
tion reduces the pericyte coverage of microvessels in astro-
cytic tumours [J]. J Neuro-oncol, 2019, 143(2): 187-196.
[9] Mohme M, Schliffke S, Maire CL, et al. Immunophenotyping
of newly diagnosed and recurrent glioblastoma defines
distinct immune exhaustion profiles in peripheral and
tumor-infiltrating lymphocytes [J]. Clin Cancer Res, 2018,
24(17): 4187-4200.
[10] Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase
mutations in gliomas [J]. Neuro-oncol, 2016, 18(1): 16-26.
[11] Fan J, Kamphorst JJ, Rabinowitz JD, et al. Fatty acid label-
ing from glutamine in hypoxia can be explained by isotope
exchange without net reductive isocitrate dehydrogenase
(IDH) flux [J]. J Biol Chem, 2013, 288(43): 31363-31369.
[12] Li F, He X, Ye D, et al. NADP(+)-IDH mutations promote
hypersuccinylation that impairs mitochondria respiration
and induces apoptosis resistance [J]. Mol Cell, 2015, 60(4):
661-675.
[13] Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of gluta-
minase preferentially slows growth of glioma cells with
mutant IDH1 [J]. Cancer Res, 2010, 70(22): 8981-8987.
[14] Fujii T, Khawaja MR, DiNardo CD, et al. Targeting isoci-
trate dehydrogenase (IDH) in cancer [J]. Discov Med, 2016,
21(117): 373-380.
[15] Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting
mutant IDH1 induces antitumour immunity [J]. Nature,
2014, 512(7514): 324-327.
[16] Weenink BAS, van Brakel Mandy, Wijers REBECCA, et al.
Lack of B and T cell reactivity towards IDH1R132H in
blood and tumor tissue from LGG patients [J]. J Neuro-
oncol, 2019, 144(1): 79-87.
[17] Rashidian J, Copaciu R, Su Q, et al. Generation and perfor-
mance of R132H mutant IDH1 rabbit monoclonal antibody
[J]. Antibodies (Basel), 2017, 6(4): 22.
[18] Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor
of mutant IDH1 delays growth and promotes differentiation
of glioma cells [J]. Science, 2013, 340(6132): 626-630.
[19] Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in
mutant IDH2 relapsed or refractory acute myeloid leukemia
[J]. Blood, 2017, 130(6): 722-731.
[20] Konteatis Z, Artin E, Nicolay B, et al. Vorasidenib (AG-
881): a first-in-class, brain-penetrant dual inhibitor of
mutant IDH1 and 2 for treatment of glioma [J]. ACS Med
Chem Lett, 2020, 11(2): 101-107.
相似文献/References:
[1]付 锴 江普查 宫 睿 王 伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(05):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳 琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫 珊 徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮 夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(05):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民 褚会松 田 甜 王昆鹏 杨国军 杨立军 王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(05):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述 王 辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰 姚庆和 李晓辉 龙宇波 陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(05):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘 靖 吴立权 黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(05):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘 炎 杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明 胡新华 刘 永 陈 玖 刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]